Researchers Coax Retinal Muller Glia Cells to Become Regenerating Neurons that Function

September 1, 2017: By Joan McKenna

1 Ophthalmic NewsResearchers have coaxed retinal Müller glia cells in an injured mouse eye to become regenerating neurons that become part of the eye’s circuitry, according to a study published July 26 in Nature.

The study, by Tom Reh, PhD, and his team at the UW Medicine in Seattle, was funded in part by the National Eye Institute.

Müller glia cells are retinal cells that support the health and functioning of neighboring neurons and also exhibit regenerative ability.

Earlier work by the team showed that activating a transcription factor called Ascl1 in newborn mice could direct Müller glia to become retinal neurons that activated genes involved in regeneration. However, in older mice, those genes became inaccessible.

Using the anti-cancer agent trichostatin A (TSA) made the genes accessible again, the scientists found.

For this study, the team used an adult mouse model genetically engineered to express Ascl1 in Müller glia in response to tamoxifen, a commonly used breast cancer drug.

They injected the mice with TSA and tamoxifen. Over the next several weeks, the shape and behavior of the cells showed evidence of regeneration.

About two weeks following injury, the cells responded to light as if they were interneurons, retinal cells that transmit signals from photoreceptors to the brain.

The cells also formed functioning synapses, or connections from one neuron to another, and had integrated with retinal cells that convey signals to the brain.

Reh said the approach could be useful for treatment of acute eye injuries and central retinal arterial occlusion. Reh’s lab is investigating other types of regenerative strategies to address all the retinal cell types.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

FDA Advisory Panel to Review Aerie’s Rhopressa in October

Johnson & Johnson Vision Acquires Online Contact Lens Business Sightbox

Novartis Returns OUS Rights for Jetrea to ThromboGenics

Eyevance Licenses Zerviate from Nicox for US Commercialization

Two Eye Projects Fail to Make Final Round for $100M Grant

Ophthotech Begins Phase IIa Trial for Zimura in Wet AMD

Graybug Vision Begins Phase I/II Trial for Candidate in Wet AMD

BioTime Receives $1.56 Million NIH Grant to Advance OpRegen for Dry AMD

FDA Approves Mvasi, a Biosimilar of Avastin Co-developed by Amgen, Allergan

Carl Zeiss Meditec Launches Zeiss Clarus 500 Ultra-Widefield Fundus Imaging System in US

Imprimis Appeals to Public Sentiment in Fiery Response to Allergan Lawsuit

Roche’s Lampalizumab Fails in Phase III Study in Geographic Atrophy

Aldeyra Reports Positive Phase IIa Results for Dry Eye Candidate ADX-102

US Denies Coherus’ Petitions Challenging AbbVie’s Patent for Humira

Ocular Therapeutix Names Michael Goldstein, MD, Chief Medical Officer

PhysIOL Agrees to Acquire Majority Stake in Italian Optikon

Rayner Creates US Subsidiary in New York

Inotek to Merge with Gene Therapy Startup Rocket

Allergan Agrees to $13.75 Million Deal with Tribe to Protect Restasis Patents

Ellex to Boost Production of iTrack Microcatheters to 50 Thousand a Year

Coming soon

2017 Retinal Pharmaceuticals and Biologics Report: A Global Market Analysis for 2016 to 2022